{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:32:34Z","timestamp":1764174754529,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.canep.2019.101619","type":"journal-article","created":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T11:39:26Z","timestamp":1571485166000},"page":"101619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Variations in prostate biopsy recommendation and acceptance confound evaluation of risk factors for prostate cancer: Examining race and BMI"],"prefix":"10.1016","volume":"63","author":[{"given":"Catherine M.","family":"Tangen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannette","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathee","family":"Till","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phyllis J.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Barrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Scott","family":"Lucia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.canep.2019.101619_bib0005","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1002\/ijc.29408","article-title":"The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era","volume":"137","author":"Jahn","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canep.2019.101619_bib0010","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level, or = 4.0 ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.canep.2019.101619_bib0015","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/sj.bjc.6604973","article-title":"Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening","volume":"100","author":"Pashayan","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canep.2019.101619_bib0020","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/oxfordjournals.aje.a009698","article-title":"Asymptomatic incidence and duration of prostate cancer","volume":"148","author":"Etzioni","year":"1998","journal-title":"AJE"},{"key":"10.1016\/j.canep.2019.101619_bib0025","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1200\/JCO.2016.68.1965","article-title":"Biases in recommendations for and acceptance of prostate biopsy significantly affect assessment of prostate cancer risk factors: results from two large randomized clinical trials","volume":"34","author":"Tangen","year":"2016","journal-title":"J Clin. Oncol."},{"key":"10.1016\/j.canep.2019.101619_bib0030","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of aspirin on all-cause mortality in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.canep.2019.101619_bib0035","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.18.01074","article-title":"Comparison of population-based observational studies with randomized trials in oncology","volume":"37","author":"Soni","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.canep.2019.101619_bib0040","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/jamaoncol.2015.0513","article-title":"Difference in association of obesity with prostate cancer risk between US African American and Non-Hispanic White men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT)","volume":"1","author":"Barrington","year":"2015","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.canep.2019.101619_bib0045","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/jnci\/dji009","article-title":"Designing the selenium and vitamin E cancer prevention trial (SELECT)","volume":"97","author":"Lippman","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.canep.2019.101619_bib0050","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.2008.864","article-title":"Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)","volume":"301","author":"Lippman","year":"2009","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.canep.2019.101619_bib0055","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.2011.1437","article-title":"Vitamin e and the risk of prostate cancer: the selenium and vitamin e Cancer prevention trial (SELECT)","volume":"306","author":"Klein","year":"2011","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.canep.2019.101619_bib0060","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/jnci\/djj131","article-title":"Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial","volume":"98","author":"Thompson","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.canep.2019.101619_bib0065","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/0197-2456(94)00XXX-M","volume":"16","author":"Design of the Prostate Cancer Prevention Trial (PCPT)","year":"1995","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.canep.2019.101619_bib0070","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cct.2003.11.007","article-title":"Implementation of the Prostate Cancer Prevention Trial (PCPT)","volume":"25","author":"Goodman","year":"2004","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.canep.2019.101619_bib0075","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.canep.2019.101619_bib0080","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/1940-6207.CAPR-08-0092","article-title":"Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach","volume":"1","author":"Redman","year":"2008","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.canep.2019.101619_bib0085","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1158\/1055-9965.EPI-08-0938","article-title":"Serum prostate-specific antigen hemodilution among obese men undergoing screening in the prostate, lung, colorectal, and ovarian Cancer Screening trial","volume":"18","author":"Grubb","year":"2009","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.canep.2019.101619_bib0090","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.urology.2010.04.060","article-title":"Body Mass Index Adjusted Prostate-specific antigen and its application for prostate cancer screening","volume":"76","author":"Liang","year":"2010","journal-title":"Urology"},{"year":"1982","series-title":"Epidemiologic Research: Principles and Quantitative Methods","author":"Kleinbaum","key":"10.1016\/j.canep.2019.101619_bib0095"},{"key":"10.1016\/j.canep.2019.101619_bib0100","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1002\/sim.731","article-title":"Nonparametic covariance methods for incidence density analyses of time-to-event data from a randomized clinical trial and their complementary roles to proportional hazards regression","volume":"20","author":"Tangen","year":"2001","journal-title":"Stat. Med."},{"key":"10.1016\/j.canep.2019.101619_bib0105","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/sim.4780130403","article-title":"Application of sample survey methods for modelling ratios to incidence densities","volume":"13","author":"LaVange","year":"1994","journal-title":"Stat. Med."},{"issue":"12","key":"10.1016\/j.canep.2019.101619_bib0110","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/1055-9965.EPI-14-0724","article-title":"Retention of black and white participants in the Selenium and Vitamin E Cancer Prevention Trial (SWOG-Coordinated Intergroup Study S0000)","volume":"23","author":"Arnold","year":"2014","journal-title":"Cancer Epidemiol. Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.canep.2019.101619_bib0115","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bju.13314","volume":"117","author":"Poyet","year":"2016","journal-title":"BJU Int."},{"issue":"2","key":"10.1016\/j.canep.2019.101619_bib0120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00345-011-0818-5","article-title":"W. Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group","volume":"30","author":"Ankerst","year":"2012","journal-title":"World J. Urol."},{"issue":"3","key":"10.1016\/j.canep.2019.101619_bib0125","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/oxfordjournals.aje.a114131","article-title":"Confounding and misclassification","volume":"122","author":"Greenland","year":"1985","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.canep.2019.101619_bib0130","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.0006-341X.2000.00779.x","article-title":"Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests","volume":"56","author":"Robins","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.canep.2019.101619_bib0135","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","article-title":"Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men","volume":"11","author":"Hern\u00e1n","year":"2000","journal-title":"Epidemiology"},{"key":"10.1016\/j.canep.2019.101619_bib0140","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782119301304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782119301304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T05:26:23Z","timestamp":1761801983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782119301304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":28,"alternative-id":["S1877782119301304"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2019.101619","relation":{},"ISSN":["1877-7821"],"issn-type":[{"type":"print","value":"1877-7821"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Variations in prostate biopsy recommendation and acceptance confound evaluation of risk factors for prostate cancer: Examining race and BMI","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2019.101619","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101619"}}